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Preface
The Swedish Criteria Group for Occupational Standards (SCG) of the Swedish National
Institute for Working Life (NIWL) has engaged Professor Gunnar Johanson at NIWL,
Sweden, to write this criteria document concerning ethylene glycol monomethyl ether and
ethylene glycol monomethyl ether acetate. Based on this document the Criteria Group will
present a report to be used as the scientific background material by the National Board of
Occupational Safety and Health in their proposal for an occupational exposure limit.
Johan Högberg Johan Montelius
Chairman Secretary
Criteria Group Criteria Group
Abbreviations of glycol ethers and their metabolites
DEGDME diethylene glycol dimethyl ether
EAA ethoxyacetic acid
EGEE ethylene glycol monoethyl ether, 2-ethoxyethanol
EGEEA ethylene glycol monoethyl ether acetate, 2-ethoxyethyl acetate
EGME ethylene glycol monomethyl ether, 2-methoxyethanol
EGMEA ethylene glycol monomethyl ether acetate, 2-methoxyethyl acetate
MAA methoxyacetic acid
MALD methoxyacetaldehyde
PGME propylene glycol monomethyl ether
PGMEA propylene glycol monomethyl ether acetate
Contents
Abbreviations
1. Introduction 1
2. Physical and Chemical Properties 1
2.1. Ethylene glycol monomethyl ether (EGME) 1
2.2. Ethylene glycol monomethyl ether acetate (EGMEA) 2
2.3. Occurrence, production and use 2
3. Occupational Exposure 3
4. Toxicokinetics 3
4.1. Uptake 3
4.2. Distribution 4
4.3. Biotransformation 5
4.4. Excretion 5
4.5. Kinetic interactions 6
5. Biological Monitoring 7
6. Mechanisms of Toxicity 8
7. Effects in Animals and In Vitro Studies 9
7.1. Irritation and sensitisation 9
7.2. Acute toxicity 9
7.3. Short-term toxicity 9
7.4. Long-term toxicity/carcinogenicity 10
7.5. Mutagenicity and genotoxicity 10
7.6. Reproductive and developmental toxicity 11
7.6.1. Effects in males 11
7.6.2. Effects in females 12
7.6.3. Effects in offspring 13
7.7. Immunotoxicity 14
7.8. Other effects 16
8. Observations in Man 17
8.1. Acute effects 17
8.2. Effects of repeated exposure on organ systems 17
8.3. Genotoxic effects 18
8.4. Carcinogenic effects 18
8.5. Reproductive and developmental effects 19
8.5.1. Effects in men 19
8.5.2. Effects in women 19
8.5.3. Teratogenic effects 22
9. Dose-Effect and Dose-Response Relationships 23
10. Conclusions 33
11. Summary 34
12. Summary in Swedish 35
13. References 36
11. Introduction
Ethylene glycol monomethyl ether (EGME) and ethylene glycol monomethyl
ether acetate (EGMEA) belong to the family of so called glycol ethers. The term
glycol ethers refers to alkyl derivatives of diols such as ethylene and propylene
glycol. The most commonly encountered glycol ethers are colourless liquids with
mild ethereal odours.
Previously published criteria documents and toxicity reviews of EGME and
EGMEA include those by the Nordic Expert Group for Criteria Documentation
(38), the UK Health and Safety Executive (47), the WHO International Pro-
gramme on Chemical Safety (48), the US National Institute for Occupational
Safety and Health (86), and the European Centre for Ecotoxicology and
Toxicology of Chemicals (25).
2. Physical and Chemical Properties
2.1. Ethylene glycol monomethyl ether (EGME) (25, 48, 98, 113)
Chemical name 2-methoxyethanol
CAS registry number 109-86-4
Synonyms methyl cellosolve
methyl glycol
Structural formula CH3–O–CH2–CH2–OH
Molecular weight 76.09
Density 0.96 (20° C)
Boiling point 124 ° C
Freezing point -85.1 ° C
Vapour pressure 1.3 kPa (9.7 mm Hg) (20 ° C)
Evaporation rate 0.5 (butylacetate = 1)
Concentration in saturated air 12 800 ppm (25 ° C)
Relative density (air = 1) 2.6
Conversion factors 1 ppm = 3.11 mg/m3 (20° C)
1 mg/m3 = 0.322 ppm (20° C)
22.2. Ethylene glycol monomethyl ether acetate (EGMEA) (25, 48, 98, 113)
Chemical name 2-methoxyethyl acetate
CAS registry number 110-49-6
Synonyms 2-methoxyethanol acetate
methyl cellosolve acetate
methyl glycol acetate
Structural formula CH3–O–CH2–CH2–O–CO–CH3
Molecular weight 118.13
Density 1.005 (20° C)
Boiling point 145 ° C
Freezing point -65 ° C
Flash point 55.6 ° C (open cup)
Vapour pressure 0.27-0.50 kPa (2.0-3.7 mm Hg) (20 ° C)
Evaporation rate 0.3 (butylacetate = 1)
Concentration in saturated air 3 100-6 000 ppm (25 ° C)
Relative density (air = 1) 4.07
Conversion factors 1 ppm = 4.90 mg/m3 (20° C)
1 mg/m3 = 0.2 ppm (20° C)
EGME and EGMEA are highly flammable, colourless, volatile liquids at room
temperature. They have a mild, sweet, ethereal odour and a bitter taste. These
ethers have very good solubility properties and are miscible with water as well as
a large number of polar and non polar organic solvents.
EGME is produced by reacting ethylene oxide with methanol. EGMEA is
produced from EGME by conventional esterification. Commercial EGME
contains up to 0.1% methanol, up to 0.1% diethylene glycol monomethyl ether
and up to 0.02% ethylene glycol as impurities (25, 48).
2.3. Occurrence, production and use
EGME and EGMEA do not occur naturally. Internationally,  reported areas of use
include paints, lacquers, stains, inks and surface coatings, silk-screen printing,
photographic and photo lithographic processes, e.g. in the semiconductor industry,
textile and leather finishing, production of food-contact plastics, and anti-icing
additive in hydraulic fluids and jet fuel (Mellan 1977, in (48)). In 1993, EGME
was listed in 23 chemical products in Sweden with an estimated use of about 260
tonnes per year. EGME was predominantly used as a solvent, but also as an
ingredient in paints and lacquers. EGMEA was not listed (55). By 1997, EGME
was listed in 27 products with an annual use of 19 tonnes, with the dominating use
as a photoresist in the telecommunications industry. EGMEA was used in 3
products with a total annual use below 0.1 ton (personal communication, the
Products Register, Swedish Chemicals Inspectorate). Since 1994, EGME and
EGMEA are listed as reproductive toxicants by the European Union and are not
3allowed in consumer’s products (Directive 94/60/EG from the European
Parliament and Council).
3. Occupational Exposure
In a survey of European manufacturing sites, time-weighted averages of 9.3 ppm
EGME and 0.9 ppm EGMEA were reported (ECETOC 1985 in (48)). A
compilation of ambient air levels during different work tasks in the United States
indicated geometric means between 1 and 23 mg/m3 (0.4-7.4 ppm) EGME and
between 0.8 and 2.0 mg/m3 (0.2-0.4 ppm) EGMEA (US EPA 1987, in (48).
Ambient air monitoring in the breathing zone indicated geometric means of 0.1
ppm EGME and 0.01 ppm EGMEA (93).
In a study of 78 Belgian industries with reported use of glycol ethers EGME
was detected in 14 and EGMEA in 15 out of 262 air samples. Levels of 4-5 mg/m3
(0.8-1.0 ppm) EGMEA were measured during printing, 6-137 mg/m3 (2-44 ppm)
EGME during painting, 3-16 mg/m3 (1-5 ppm) EGME and 2 mg/m3 (0.4 ppm)
EGMEA during car repair, and 0.4-143 mg/m3 (0.1-29 ppm) EGMEA during
other tasks (129).
In an extensive study of glycol ether exposure in 55 French companies covering
18 sectors of activity the highest exposure to EGME was seen in the electronic
industry during use of photoresist varnishes in the production of printed-circuit
boards. In this activity the average ambient air level of EGME was 2.1 ppm (range
0.1 - 18 ppm). EGME was also detected (<0.1 - 0.2 ppm) in car painting. Presence
of the metabolite methoxyacetic acid (MAA) in both pre- and post-shift urine
samples from workers engaged in the fabrication of paints and in painting and
varnishing furniture strongly suggested exposure to EGME or EGMEA also in
these sectors (132).
Personal monitoring of 36 shipyard painters (102 samples) revealed time-
weighted averages of between 0 and 18 mg/m3 (5.8 ppm) EGME with a mean of
2.6 mg/m3 (0.8 ppm) (114).
4. Toxicokinetics
The chemical structures and solubility properties of EGME and EGMEA suggest
that both substances are efficiently absorbed by all routes and rapidly distributed
to the different tissues.
4.1. Uptake
In male volunteers exposed at rest to 5 ppm EGME for 4 h the respiratory uptake
was 76% of the inhaled amount of EGME (37). In contrast to most other more
volatile and less polar solvents, only a negligible fraction is exhaled after exposure
has ended. The high relative uptake and negligible post-exposure exhalation may
4be explained by the extremely high water:air and blood:air partition coefficients of
EGME (53).
The average absorption rate of EGME through isolated, thawed human epi-
dermal preparations in vitro was 2.8 mg/h per cm2 of epidermis with a lag time for
penetration of 1-3 h (24). Out of  9 glycol ethers tested EGME had the by far
highest percutaneous absorption rate (53).
In an early study human volunteers were exposed to 15 ml EGME via a closed
plastic vessel attached to the arm (area 12.5 cm2). Two hours after application the
concentrations of EGME in blood were 200-300 m g/ml, or one order of magnitude
higher than recorded in similar experiments conducted with ethanol, acetone, and
methylacetate (81). The vessel used for blood sampling was not reported and no
quantitative estimates of the percutaneous absorption rate can be made from this
study.
In a more recent study five volunteers were exposed to liquid or vaporised
EGME (59). Exposure to liquid EGME was performed on the forearm (skin area
27 cm2, duration 15 min) and the percutaneous absorption rate was obtained by
measuring the excretion of the EGME metabolite MAA in urine. The average
value 2.9 mg/cm2/h was very close to that obtained in the previously mentioned in
vitro study by Dugard et al. (24). Kezic et al. (59) also exposed the hand and
forearm (skin area approximately 1000 cm2) to 4000 mg/m3 EGME for 45 min. By
comparing the two experiments, the authors estimated that, upon whole-body
exposure to EGME vapour, dermal absorption accounts for 55% and respiratory
absorption for 45% of the total systemic uptake. Percutaneous uptake during
contact of both hands and forearms (skin area 2000 cm2 or 10% of the total body
surface area) with liquid EGME for 60 min was estimated to exceed by 100 times
the inhalation uptake during an 8-h exposure to 16 mg/m3 (5 ppm) EGME vapour
(59).
4.2. Distribution
EGME appears to be rapidly and evenly distributed in tissues, with the exception
of adipose tissue. Thus, the tissue:blood partition coefficients determined in vitro
using material from mice and rats vary between 0.9 (skin) and 1.9 (extra
embryonic fluid). EGME has a low solubility in fat with an olive oil: blood
partition coefficient of 0.02. The slightly higher reported adipose tissue: blood
partition coefficients of 0.04 and 0.1 can be attributed to the presence of water and
other non-fat components in adipose tissue. Judging by partition coefficients, the
metabolite MAA also appears to be evenly distributed to the tissue (53).
Whole-body autoradiography in mice showed that, following administration of
14C-labelled EGME, the radioactivity is preferentially localised to the liver,
urinary bladder, kidney, bone marrow, and epididymis. Further, the autoradio-
graphy studies suggest a rapid distribution to various tissues (2).
54.3. Biotransformation
EGMEA is rapidly and extensively hydrolysed to EGME by carboxyl esterases in
the nasal epithelium, liver, kidneys, lungs, and blood, as shown with tissues from
mouse, rat, dog, and rabbit (115). Such esterase's are also present in human
tissues, as indicated by rapid disappearance of ethylene glycol monoethyl ether
acetate (EGEEA) from human blood (54) and the appearance of ethylene glycol
monoethyl ether (EGEE) in exhaled breath from humans exposed to EGEEA (36).
The dominating metabolic pathway of EGME is oxidation via methoxyacetal-
dehyde (MALD) to methoxyacetic acid (MAA). The biological half time of MAA
in serum or plasma has been reported to about 6 h in mouse and 20 h monkey. The
half time of the decrease in urinary excretion in man was 77 h (53). Testis is
capable of metabolising EGME via alcohol dehydrogenase (shown in mouse and
rat but neither hamster, guinea pig, rabbit, dog, cat, nor man) and aldehyde
dehydrogenase (shown in all these species) to MAA (78).
In addition to MAA, nine EGME metabolites have been identified in mice and
rat urine. The most extensive study in this respect was performed by Jenkins-
Sumner and co-workers (51), who analysed urine samples from animals dosed
with 13C-labelled EGME by two-dimensional nuclear magnetic resonance
spectroscopy and identified ethylene glycol, glycolic acid, glycine, methoxyethyl
ß-D-glucuronide, methoxyethylsulfate, MAA, methoxyacetyl ß-D-glucuronide,
methoxyN-acetylglycine, methoxycitrate and methoxybutenoic acid. Acetate
given together with EGME reduced the percentage of EGME metabolites
incorporated into intermediary metabolism. These results show that EGME may
enter the Krebs cycle via formation of methoxyacetyl-Coenzyme A (51). It has
been speculated (73) that this ”false substrate” of Krebs cycle may be related to
reproductive effects of EGME described below.
The analyses (51) further show that demethylation of EGME may occur
(resulting in ethylene glycol). A case report suggests that demethylation of EGME
may also occur in humans. Thus, one of two men who had accidentally ingested
about 100 ml EGME developed high oxalate levels in urine in spite of massive
treatment with ethanol (87).
4.4. Excretion
EGME is mainly eliminated from the body via excretion of metabolites in urine.
In an experiment with male volunteers exposed at rest to 5 ppm EGME for 4 h,
the total (extrapolated) amount of MAA excreted in urine was calculated to 86%
of the inhaled EGME, on an equimolar basis (37). Due to the extremely high
water: air and blood: air partition coefficients of approximately 36000 and 33000,
respectively (54), it can be assumed that the amounts of EGME eliminated via
exhaled air is negligible.
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Figure 1. Proposed metabolic pathways of 2-methoxyethyl acetate and 2-
methoxyethanol. Modified from Jenkins-Sumner et al. (51). Square brackets denote
postulated metabolites.
4.5. Kinetic interactions
Following an intraperitoneal injection of EGME (150 mg/kg) in rats, the rate of
elimination of EGME  was significantly higher in males (average half time
49 min) than in females (28 min). In contrast, there was no difference in the
elimination of MAA (half times 12.6 and 14.1 h) after an intraperitoneal dose of
100 mg/kg EGME (1).
7The transformation of EGME to MAA can be inhibited by ethanol, as shown in
rat experiments. Thus, in adult female rats exposed for 2 h to 1600 ppm, EGME
reached three times higher concentrations in blood after intraperitoneal pre-
treatment with ethanol (20 mmol/kg body weight). After co-administration of
EGME (10 mmol/kg) and ethanol (20 mmol/kg), EGME in blood reached a higher
level and remained constant for several hours, or as long as ethanol levels in blood
were above 3 mmol/L (99). The importance of alcohol dehydrogenase was shown
by an almost complete inhibition of EGME metabolism in rats treated with
pyrazole (79).
It is commonly recommended that glycol ether intoxication should be treated
with ethanol. However, in rats orally treated with EGME (10 mmol/kg)
co-administration of alcohol (ethanol, n-propanol, or n-butanol, 10 or
30 mmol/kg) did not modify the testicular toxicity, measured as the urinary
creatine:creatinine ratios at 24 h and 48 h, nor the 24 h cumulative excretion of
MAA. The authors concluded that alcohol treatment merely delays, and does not
alter, the metabolism of EGME (76). This interpretation is, however, contra-
indicated by the previously referred metabolism study by Jenkins-Sumner (51).
5. Biological Monitoring
It is likely that dermal uptake contributes significantly to, or even dominates, the
total uptake of EGME and EGMEA. In addition, inhalation uptake is highly
dependent on pulmonary ventilation and thus on physical work load. These
considerations point to the need of biological monitoring of exposure (52). The
recovery of MAA in urine accounts for about 85% of the inhaled dose of EGME
in human experiments (37), pointing towards MAA in urine as the biological
indicator of choice.
MAA was detected in both pre- and post-shift urine samples from workers
engaged in the manufacture of printed-circuit boards, fabrication of paints and in
painting and varnishing of furniture. The study did not present any relation
between ambient air levels and urinary MAA (132).
Exposure to ethylene glycol ethers was monitored for an entire work week in 8
silkscreen printers, by personal air sampling and by analysis of urine samples with
regards to alkoxyacetic acid metabolites. Linear regression analysis suggested that
5 daily  8-h exposures to 0.5 ppm EGMEA correspond to a urinary excretion of
MAA of 3 mmol/mol creatinine 14 - 16 h after the last shift, i.e. Saturday mor-
ning. No correlation was seen between EGMEA in air and MAA in urine sampled
end of shift (64).
Comparable results have been obtained in an experimental study with seven
male volunteers exposed at rest for 4 h to 16 mg/m3 (5 ppm) EGME. The urinary
excretion of MAA reached a maximum of about 3 m g/min 2 - 5 h after exposure.
The excretion then decreased over time, with a half time of 77 h and reached a
rate of about 2 m g/min 20 h later (i.e. the next morning).
8The relation between exposure to EGME and internal levels of the active meta-
bolite MAA may be deduced from two studies. An intravenous bolus dose of
250 mg EGME per kg body weight and an 8-h continuous subcutaneous infusion
of a total dose of 400 mg/kg resulted in the same maximum level of MAA in
plasma of 5 mmol/L (118). Simulations performed with a physiologically based
toxicokinetic model suggest that daily 8-h exposures to 5 ppm EGME result in
plasma MAA levels of about 0.05 mmol/L in mouse, rat, and man (128).
6. Mechanisms of Toxicity
Human erythrocytes were studied in vitro by means of electron paramagnetic
resonance spin-labelling techniques. MAA increased the protein-protein inter-
actions of cytoskeletal proteins in a concentration-dependent manner in the
interval 0-5 mmol/L, whereas EGME was ineffective. Membrane fluidity was not
affected. The authors suggest that MAA may give rise to teratologic insult by
interacting not with lipid components but with certain, perhaps specific, protein
components such as transport proteins, cytoskeleton proteins, or neurotransmitter
receptors (67).
A 30-min treatment of cultured myometrial cells with 32 or 63 mmol/L EGME
significantly decreased dye transfer to adjacent cells from 90% to 71% and 63%,
respectively, suggesting inhibition of gap junctional communication. The effect
disappeared after 2 h in the continued presence of EGME. MAA was ineffective
at equimolar concentrations (71). The high concentrations required suggest that it
is unlikely that gap junctional inhibition is the primary mechanism for develop-
mental effects of EGME.
A number of substances, namely formate, acetate, glycine, glucose, serine, and
sarcosine, involved in the synthesis of purine and pyrimidine bases, reduce or
eliminates the malformations and testicular damage induced by EGME in labora-
tory animals. Formate is particularly effective in attenuating the teratogenic effect
of EGME. Formate is predominantly metabolised via the folate-dependent 1-
carbon oxidation pathway, a source in many biosynthetic pathways including that
of purine and pyrimidine. Thus, EGME may interfere with the DNA and/or RNA
synthesis and thereby influence normal cell proliferation (74, 75). D-Serine is a
more efficient attenuator than L-serine. Both enantiomers delayed the absorption
of EGME from the gastrointestinal tract, however, comparison of data from
different routes of administration and different dose levels suggests that the
protective effect is not only a secondary result of altered toxicokinetics of EGME
(15).
In vitro studies show that MAA is an efficient competitive inhibitor of sarcosine
dehydrogenase, the enzyme involved in the transformation of sarcosine to glycine.
Inhibition constants of 1.8 mmol/L (32) and 0.26 mmol/L (95) have been reported.
mRNA differential display was used to identify gene expression changes in
cultured rat germ cells treated with 5 mmol/L EGME or MAA for 24 h. Up-
regulation of oxidative stress proteins were found in both pachytene sperma-
9tocytes and Sertoli cells, whereas other proteins were down-regulated. The same
changes in expression pattern were seen in vivo in  rats after an oral dose of
250 mg/kg EGME or MAA (117).
7. Effects in Animals and In Vitro Studies
7.1. Irritation and sensitisation
Neat EGME or EGMEA were applied on the shaved skin of rabbits for 4 h.
Readings of erythema and edema was performed according to the Draize scale up
to 72 h after removal of the patch. Both substances were classified as non-irritants
according to the EEC Directives (50).
EGME was tested for eye irritancy in rabbits according to the OECD Guidelines
of 1981. Neat EGME (100 m l) was applied in the lower conjunctival sac for up to
96 h and the Draize scoring criteria were used. EGME was classified as not
irritating to eyes (49).
7.2. Acute toxicity
The acute toxicity of EGME is moderate. LD50 values of between 2.1 and 3.4 g/kg
body weight have been reported after oral and intraperitoneal administration to
mice and rats. The corresponding values in guinea pigs and rabbits are 0.95 and
0.9-1.5 g/kg, respectively. A dermal LD50 in rabbit of 1.3 g/kg has been reported.
The LC50 of inhalation was 4600 mg/m3 (1480 ppm) in mice (48). A 4-h exposure
of male rats to EGME vapours resulted in testicular atrophy at 1000 ppm and
spermatid damage at 625 ppm. These effects occurred within 24 h (102).
The acute toxicity of EGMEA is of the same magnitude as EGME. Thus, oral
LD50 values of 3.9 g/kg in rats and 1.3 g/kg in guinea pigs and a dermal LD50 of
5.6 g/kg in rabbits have been reported (48).
For comparison, the oral LD50 of MAA in water solution is reportedly between
1 and 1.5 g/kg (25).
7.3. Short-term toxicity
Repeated short-term exposure to EGME or EGMEA via gavage, dermal applica-
tion, drinking water, or inhalation results in similar effects in several animal
species. These effects include reduced organ weights of the thymus, spleen and
testes, reduced number of erythrocytes, leukocytes and thrombocytes, lowered
hematocrit, depression of bone marrow cellularity, and increased fraction of
immature granulocytes. Sperm differentiation is affected in a specific phase, late
pachytene, which is later expressed as oligo- or azoospermia. The toxicity pattern
is independent of the route of exposure (25, 48). Oral and inhalation toxicity
studies are compiled in Tables 1 and 2, respectively.
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7.4. Long-term toxicity/carcinogenicity
No cancer studies of either EGME or EGMEA have been reported. McGregor
concluded in a carcinogenic evaluation of glycol ethers, based on data published
up to 1994, that the only experimental basis for suspicion of carcinogenicity is the
Salmonella-positive results (described in the following section) (72).
7.5. Mutagenicity and genotoxicity
With the exceptions itemised in the following, EGME and its metabolite MAA
were negative in all genotoxicity assays including the Ames’ test for all Salmo-
nella strains tested, with and without addition of metabolising systems (for review
see (72)).
After testing with a series of Salmonella strains, with and without metabolic
activation, the mutagenicity of EGMEA was judged by two independent
laboratories to be weak and questionable, respectively (136).
EGME induced mutations in the gpt gene in a Chinese hamster ovary cell line
(CHO-AS52), but no mutations in the hprt gene in another cell line
(CHO-K1-BH4) (5, 14, 70). The intermediary metabolite metoxyacetaldehyde
(MALD) was weakly mutagenic in the strain TA 97a and slightly more so after
metabolic activation (42). MALD induced mutations, sister chromatid exchanges,
and chromosomal aberrations in Chines hamster ovary (V79) cells in vitro in the
concentration interval 5-40 mmol/L. Chromosomal damage was noted in human
lymphocytes following treatment with 40 mmol/L MALD for 1 h or 2.5 mmol/L
for 24 h (13). However, no chromosomal damage could be detected in vivo in
mice given oral doses of up to 1000 mg/kg MALD or up to 2500 mg/kg EGME
(6).
A number of glycol ethers and their aldehyde and acid metabolites were tested
for genotoxic and epigenetic effects in various short term test systems. The effects
sought were gene mutations at the hprt locus (V79 cells), sister chromatid
exchanges (V79 cells), chromosomal aberrations (V79 cells and human lympho-
cytes), micronuclei (V79 cells and mouse bone marrow), alterations of the mitotic
division and aneuploidy (V79 cells), morphological transformation (Syrian
hamster embryo cells), and inhibition of intracellular communication (V79 cells).
Reduced cell division was noted in the concentration intervals 100-1000 mmol/L
EGME, 1-10 mmol/L MAA and 0.1-1 mmol/L MALD. Mutations were induced at
1-10 mmol/L MALD and sister chromatid exchanges and chromosomal aberra-
tions at 0.1-1 mmol/L MALD. Increased number of micronuclei and mitotic
disturbances were seen in V79 cells at 65 mmol/L EGME, 0.12 mmol/L MALD
and 3.2 mmol/L MAA. Increased number of morphological transformations in
embryonic cells were seen at 0.1-0.3 mmol/L MALD. The authors judged the
results to be weakly positive with respect to micronuclei and mitotic disturbances
from EGME and MAA and clearly positive with respect to the other endpoints
and MALD (27).
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Male rats were gavaged with 500, 1000, or 1500 mg/kg EGME. Animals were
killed 2 or 5-6 weeks after treatment and bone marrow cells and testes cells were
prepared and investigated for DNA damage by the comet assay. A significant
dose-dependent increase in DNA damage was seen in the germ cells 2 weeks but
not 5-6 weeks after treatment. No effect in bone marrow could be detected (4).
EGMEA was tested for induction of aneuploidy in two Drosophila melano-
gaster systems. Aneuploidy, mainly expressed as chromosome losses, was seen in
the oocytes from young adult females exposed to 32000 and 42000 ppm, but not
to 3200 and 4200 ppm EGME in the food (89).
7.6. Reproductive and developmental toxicity
A large number of animal studies gives a uniform picture that both EGME and
EGMEA cause reproductive toxicity in laboratory animals of both sexes. The
effects in male animals include reduced testes weight, histopathological changes
in the testes and reduced sperm count. These effects are reversible. At higher
doses testicular atrophy and azoospermia are seen. Effects in female animals
include reduced fertility, increased number of dead and resorbed foetuses,
impaired postnatal survival, and increased number of skeletal variations,
malformations of the extremities and visceral malformations. Effects on the
offspring are seen at doses with no overt maternal effects. Higher doses cause
100% foetal death. The reproductive effects have been shown in a number of
animal species and for all main routes of exposure. The severity of the effects on
the foetus is highly dependent on the time of exposure (25, 48). Selected studies
are listed in Tables 1 and 2. The most recent reproductive toxicity studies are
summarised in the following paragraphs.
7.6.1. Effects in males
Groups of 6-7 rabbits were given EGME via drinking water 5 days/week for 12
weeks (0, 12.5, 25, 37.5 or 50 mg/kg/d). A dose-dependent decrease over time in
sperm quality was seen. The effects reached statistical significance at 37.5 and
50 mg/kg/d, the most marked effect being reduced number of sperms per
ejaculate. Histological evaluation revealed slightly disturbed spermatogenesis at
25 mg/kg, expressed as a decrease in the number of round spermatids per Sertolic
cell. At 37 mg/kg spermatogenesis was markedly disrupted and at 50 mg/kg it was
almost completely destructed in 5 of 7 rabbits. No effects on libido or fertility
were seen in those rabbits which still had sperm production. The authors con-
cluded that, with respect to spermatogenesis, rabbits are about ten times more
sensitive to EGME than mice and rats (9, 31).
Male mice were exposed to EGME by gavage for 5 days (0, 50, 200, 750, or
1500 mg/kg/d) and then mated once a week with unexposed female mice for the
next 7 weeks. An aggregation chimera assay was used to examine the trans-
mission of impaired viability in the males to their progeny preimplantation
embryos. Prior to their aggregation into pairs, one of the embryos was labelled
with a viable fluorescent dye to determine the relative cellular contribution from
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each partner embryo when chimeras were dissociated 30-35 h later (2-3 cell
cycles). Direct cell-cell contact of embryos derived from exposed males and
embryos from control males creates a competitive situation that has been shown to
confer a cell proliferation disadvantage to the embryo from an exposed parent.
The cell proliferation disadvantage is expressed as the ratio between the number
of cells from an experimental embryo and the total chimera cell number. Prolifera-
tion ratios were significantly decreased in all embryos fertilised by sperms
exposed at week 4, corresponding to the pachytene stage of spermatogenesis. The
authors suggest that effects induced in the spermatids are transferred to the
embryo via a non-mutagenic process (90).
Testicular response to EGME was compared in rats and guinea pigs. Single
doses of 200 or 300 mg/kg caused marked depression in dividing spermatocytes
whereas triple doses of 200 mg/kg per day for 3 days caused complete sperma-
tocyte depletion. The effects in guinea pig were less severe and also differed in
onset and histological characteristics (62). In a subsequent study the same
researchers showed that the spermatocyte degeneration is associated with
programmed cell death (apoptosis) (63).
The effects of MAA were studied in vitro in cultured rat seminiferous tubules
and human testicular tissues. Apoptosis of germ cells was seen in both species at
1 mmol/L MAA but not at lower concentrations. Addition of known calcium
channel blockers to the medium prohibited the apoptotic effect of MAA whereas
substances acting as inhibitors of calcium mobilisation from intracellular stores
were ineffective (68, 69).
Repeated exposure of rats to EGME for 10 days administered in the drinking
water at doses corresponding to 43, 87, and 220 mg/kg/d caused significant
testicular damage, reduced relative testicular weight, and reduced body weight
gain at the highest dose. In contrast, the urinary creatine: creatinine ratio was
significantly increased at the high and the mid dose and, on some days, also in the
low dose group. The authors suggest that the urinary creatine: creatinine ratio may
be a useful marker for chronic testicular damage (12).
7.6.2. Effects in females
Female reproductive toxicity of EGME was studied in vivo in rats after oral
administration of EGME and in vitro in cultured rat luteal cells after addition of
the metabolite MAA. Daily gavage of 300 mg/kg EGME resulted in a complete
suppression of cyclicity without evidence of systemic toxicity within 3 - 8 days,
whereas doses less than 100 mg/kg had no effect. The suppression of cyclicity
was associated with inhibited ovulation, hypertrophy of the corpora lutea, elevated
serum progesterone, whereas serum estradiol, follicle stimulating hormone,
luteinising hormone, and prolactin remained at baseline levels. In vitro, elevated
progesterone levels were seen already at 1 mmol/L MAA, the lowest concentra-
tion tested (19).
MAA was tested in a system with cultured human luteinised granulosa cells in
vitro. Treatment with 0-5 mmol/L MAA for 6-48 h caused an increase in pro-
gesterone that depended on both exposure duration and concentration used. The
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effect was significant at 1 mmol/L but tendencies were seen also at 0.1 and
0.5 mmol/L MAA. This implies that EGME has the potential to alter ovarian
luteal function in women (3).
Intraperitoneal injections of 250 or 500 mg/kg EGME or its metabolite MAA on
day 11 of gestation caused marked congestion, haemorrhages, necrosis and des-
quamation in the placenta. These lesions signify a disordered maternal circulation
which, according to the authors, may play a role in the embryotoxic and terato-
genic effects of EGME and MAA (60).
7.6.3. Effects in offspring
Pregnant monkeys (Macaca fascicularis) were gavaged during organogenesis
(day 20-45) with 0.16, 0.32, or 0.47 mmol/kg EGME, corresponding to daily
doses of 12, 24, or 36 mg/kg per day. The treatment caused maternal toxicity,
expressed as moderate to markedly reduced appetite and weight loss. The affected
animals were given additional nutrients by gavage. Foetuses were collected at day
100 by Caesarean section. At the highest dose level, all 8 pregnancies ended in
death of the embryo. One of the embryos lacked a digit on each forelimb, a
malformation hitherto not observed in this species. In the mid-dose group 3 of 10
and in the low dose group 3 of 13 pregnancies ended in embryonic death. These
frequencies can be compared with those of the untreated control group (0 of 6
pregnancies) and a control group dosed with 0.47 mmol/kg/d ethanol (0 of 3). No
malformations were seen in live foetuses. Based on the malformation and the
appearance of dead embryos the authors suggested that the effects seen are
directly related to exposure to EGME, and not secondary to maternal toxicity. In
an additional experiment a dose-related decrease in foetal weight was seen at day
35 but not at day 100 of gestation (105).
Male rats were exposed to 25 ppm EGME (7 h/day, 7 days/week) for 6 weeks
and then mated with unexposed females. In addition, female rats were mated with
unexposed males and then exposed to 25 ppm EGME on gestation days 7-13 or
14-20. No paternal or maternal effects were seen. Six different behavioural tests
revealed significant differences from controls only in avoidance conditioning of
offspring of mothers exposed on days 7-13. Neurochemical deviations were seen
in brains from 21 days old offspring of both the paternally and maternally exposed
groups. These deviations were numerous in the brainstem and cerebrum, and
fewer in the cerebellum and midbrain. Thus, acetylcholine was reduced to about
one third in all EGME-treated groups, as compared to the controls. Conversely,
acetylcholine increased by three-fold in the brainstem. Similar changes were seen
for norepinephrine and 5-hydroxytryptamine whereas changes in the opposite
direction were seen for dopamine. The mechanism of the neurochemical changes
was not addressed (82).
A synergistic teratogenic effect between EGME and radio frequency radiation
has been reported. Groups of 18-27 pregnant rats were gavaged with distilled water
or EGME (150 mg/kg) on day 13 of gestation with or without concurrent exposure
to radio frequency radiation at 10 MHz at an intensity (0.8-6.6 W/kg) selected to
cause a 4 ° C increase in body temperature. The number of malformations per litter
14
increased from 0% in controls to 14% in EGME only, 30% in radio frequency only
and 76% in combined treatment (83). In a follow up study, different dose levels and
different dosing days were tested. As in the previous study, a synergistic effect was
seen at high EGME doses (75-150 mg/kg), whereas low doses (20 and 40 mg/kg)
produced antagonistic effects between EGME and radiation (84, 85).
Daily oral dosing of female rats with 50 mg/kg/d EGME on day 7-13 resulted in
prolonged gestation length and reduced litter size, perinatal survival, and postnatal
growth. Electrocardiographic changes at 3 and 6 weeks of age, interpreted as a
intraventricular conduction delay, were seen in nearly 50% of the offspring. At a
slightly higher dose of 75 mg/kg/d there were no survivors beyond 3 days of age
(120). Daily doses of 25 mg/kg caused reduced ornithine decarboxylase activity in
the heart muscle of the offspring but no other signs of reproductive toxicity (121,
123).
The embryotoxic and teratogenic properties of EGME are highly dependent on
the timing of exposure. Thus, single oral doses of 500 mg/kg given to female mice
on day 10 through 15 of gestation caused time dependent decreases in embryo
lethality, from 100% day 10 to 5% on day 15, as compared to 2% in control
animals. A parallel decrease in malformations, from 100% to 0%, was seen (106).
Similar results have been obtained in several studies with EGME and MAA. In
one study on mice different doses of EGME were given on gestation days 8 or 9,
either as an intravenous bolus or as a subcutaneous infusion. The frequency of
exencephalies (frequency range 0-48%, dose range 0-606 mg/kg) strongly
correlated with the maximum level of MAA, but not with the area under the
concentration-time curve (AUC) of MAA, in maternal and embryonal plasma
(118). An oral dose of 10 mmol/kg (700 mg/kg) at 10.5, 11 and 11.5 days after
conception resulted in different malformation patterns in the extremities. The most
pronounced effects were seen after dosage at day 11.5 (96). In a third mouse
study, neural development was followed after subcutaneous administration of 250
mg/kg EGME on gestation day 8. Open neural tubes appeared at a higher
frequency compared to controls at all days examined (gestation days 9, 10, and
18). The most pronounced effects were seen on day 9, suggesting partial recovery
and catch-up in neurolation later during gestation (119).
Teratogenic effects of EGME  have been documented in various strains of
Drosophila melanogaster, including a strain that lacks alcohol dehydrogenase.
According to the authors this shows that EGME itself acts as a teratogen (26).
7.7. Immunotoxicity
Male mice were given different intravenous doses of bacterial endotoxin followed
by an additional intravenous dose of 950 mg/kg EGME. The EGME treatment
caused a 64-fold increase in sensitivity, in that the endotoxin LD50 changed from
17 to 0.25 mg/kg (33).
In male rats given human leukaemia cells by subcutaneous injections, all
clinical, morphological, and histological signs of leukaemia disappeared when the
animals were supplied with 2.5 mg/ml EGME via the drinking water. Addition of
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0.25 mg/ml, corresponding to a daily dose of 15 mg/kg, reduced the leukaemia
response by 50%. The closely related substance ethylene glycol monoethyl ether
(EGEE) also depressed the response, but was ten times less potent than EGME.
Seven other glycol ethers were ineffective. Experiments carried out in vitro with
the same leukaemia cell line showed a concentration dependent reduction in cell
count in the interval 1-100 m mol/L EGME. The metabolite MAA was approxi-
mately half as effective as EGME, unlike the results of teratogenic or spermato-
toxic experiments carried out by other investigators. According to the authors,
these observations suggest that cytotoxicity is not solely responsible for the
antiproliferative activity of EGME (21).
A markedly atrophic cortex and almost intact medulla were seen in the thymus
of mice gavaged with 100 or 500 mg/kg/day EGME for 5 to 10 days. Study of
thymocyte surface markers revealed a decrease in immature thymocytes in treated
animals (58).
Female rats exposed to 2000 and 6000 ppm EGME in drinking water (corre-
sponding to 161 and 486 mg/kg per day, respectively) for 21 days expressed
increased natural killer cell activity and reduced thymus weight, anti-KLH IgG
production, splenocyte gamma-interferon production (high dose only), and spleen
cell number. Male rats exposed to 1600 and 4800 ppm (200 and 531 mg/kg/d)
were similarly affected. In addition, splenocyte gamma-interferon and testis
weight reductions were seen at both dose levels and thymus atrophy and de-
pressed interleukin-2 production at the high dose (30).
A single oral dose of 125 mg/kg EGME caused a 3-fold increase and 500 mg/kg
an 8-fold increase in apoptotic index (programmed cell death) in the thymus,
compared to untreated animals. Pre-treatment with phenobarbital abolished almost
completely the apoptotic effect. In parallel, a decreased capacity of the liver to
metabolise EGME to MALD and a marked enhancement in the capacity to meta-
bolise MALD to MAA were seen (7).
Immune responses were studied in rats and mice following oral treatment with
EGME, EGMEA, MALD, and MAA at daily doses of 50, 100, 200 and
400 mg/kg for 10 days. In rats, the four substances resulted in similar immuno-
suppression in the rat, expressed as reductions in thymus and spleen weights and
antibody plaque-forming cell response. Significant effects were seen already at the
lowest dose tested and equal doses resulted in equivalent degrees of suppression.
Pre-treatment with the alcohol dehydrogenase inhibitor 4-metylpyrazole blocked
the immunosuppressive effects of EGME. Further, pre-treatment with the alde-
hyde dehydrogenase inhibitors disulfiram or cyanamide blocked the immuno-
suppression otherwise seen with EGME and MALD. Altogether, these data show
that metabolism of EGME and EGMEA to MALD or MAA is required for the
development of immunotoxic effects in rats. In a comparative study, immuno-
suppression was recorded in all rat strains tested but in none of the mouse strains.
Not even very high doses of up to 1920 mg/kg/d MAA given subcutaneously via a
miniosmotic pump caused immunosuppression in the mouse. This suggests that
the observed species differences cannot be explained by differences in bioavail-
ability or MAA biotransformation capacity (97, 107-112).
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Further studies in vitro showed that the immunosuppressive actions (decrease in
polyclonal IgM and IgG antibody responses) of EGME (effective concentrations
0.5-1.0 in mouse and 2.0 mmol/L in rat) and MAA (effective concentrations 12.5
and 25 mmol/L, respectively) were more pronounced in mouse than in rat
lymphocytes, whereas MALD was equally effective in both species (effective
concentration 0.3 mmol/l in both species). Further, immunosuppression was
markedly higher in rat lymphocytes co-cultured with mouse hepatocytes than
when co-cultured with rat hepatocytes (61). These results indicate that MALD or
some other intermediary metabolite may be the proximate immunotoxicant.
Female mice were gavaged with 100, 150 or 200 mg/kg/d EGME on days 10-17
of gestation and immunology parameters were analysed in the foetuses on day 18.
Thymus atrophy, dose dependent reduction in cellularity, and changes in thymo-
cyte pattern, suggesting impairment of thymocyte maturation, were seen in the
exposed foetuses. EGME also reduced the percentage of CD45+ leukocytic cells
in foetal liver. Addition of 10, but not 1, m mol/L MAA to foetal liver cells in vitro
impaired the proliferative capacity, expressed as a reduction in 3H-thymidine
incorporation. No effect on hepatocyte survival was seen (43).
Immune effects were studied in male rats following occluded dermal appli-
cations of 150, 300, 600, 900, and 1200 mg/kg/d EGME for 4 days. Decreases in
thymus weight were seen at all dose levels and in spleen weight at the two highest
doses. The lymphoproliferative responses to phytohemagglutinin and pokeweed
mitogen were enhanced at 1200 mg/kg/d. In a separate experiment, reductions in
antibody plaque-forming cell response to either trinitrophenyl-lipopolysaccharide
or sheep red blood cells were seen at 600 and 300, but not 150 mg/kg/d. These
effects occurred in the absence of body weight losses. Similar effects were seen
after oral administration of 25, 50, 100, and 200 mg/kg/d EGME for 4 days (131).
7.8. Other effects
EGME was ineffective whereas 0.5 mmol/L MAA caused increased osmotic
fragility in human erythrocytes in vitro. Incubation of human erythrocyte
membranes (ghosts) inhibited membrane bound acetyl cholinesterase
(IC50=5.5 mmol/L) and ATPase (IC50=1.4 mmol/L) activities (77).
Male rats exposed to 75 ppm EGMEA, 8 h per day for 4 weeks expressed
changes in serum protein patterns, revealed by two-dimensional electrophoresis.
At least 12 unidentified (out of 410) proteins were dramatically changed. Expo-
sure to isobutylacetate caused yet another protein pattern and exposure to a
combination of EGMEA and isobutylacetate caused additional changes (134).
Oral administration of 100 or 300 mg/kg/d EGME to male rats for up to 4 weeks
caused a dose dependent increase in gamma-glutamyltranspeptidase activity in
serum, liver and lungs (56). Depressed activities of the enzymes acetyl choline-
sterase and delta-aminolevulic acid dehydratase (ALA-D) were seen in erythro-
cytes, blood and bone marrow from rats 3 days after a peritoneal injection of
200 mg/kg EGME (66).
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8. Observations in Man
8.1. Acute effects
Three cases of acute intoxication after ingestion of EGME have been reported.
A man who drank half a pint of EGME died with acute haemorrhagic gastritis and
degenerative changes in the kidneys, liver and pancreas (133). Two men who
consumed approximately 100 ml EGME became mentally confused and com-
plained of weakness and nausea. They became cyanotic and developed hyper-
ventilation, tachycardia, and metabolic acidosis. One of them developed renal
failure. Both men recovered within four weeks (87).
8.2. Effects of repeated exposure on organ systems
According to older reports, repeated occupational exposure to EGME presumably
at high concentrations affects the central nervous system with symptoms such as
headache, fatigue, general weakness, drowsiness, ataxia, and irregular pupils (11,
22, 35, 91).
Six poisonings with pronounced central nervous system effects and, in one man
(the only case studied in this respect) hypocellular bone marrow, were reported in
the fifties. The men were cleaning machines in a printing shop and the effects
appeared after replacement of the cleaner solution from a mixture of heavy
aromatics and isopropanol to EGME. At reconstruction of the work procedures
ambient air levels of between 61 and 3960 ppm EGME were measured (135).
One report describes a man with apathy, somnolence and prolonged sleep time.
The man was engaged in microfilm production and was reportedly exposed to
EGME via inhalation as well as via skin. Blood examination revealed reductions
in red cell, white cell and thrombocyte counts, and in haemoglobin and
haematocrit. Air measurements revealed EGME levels between 18 and 58 ppm.
Methyl ethyl ketone and propylene glycol monomethyl ether (PGME) were
detected at lower concentrations. All haematologic parameters normalised within
a month after terminated exposure (16).
Three young women employed in a frame factory used a mixture of 30%
EGME and 70% acetone to glue together cellulose acetate frame components.
Periodic examinations revealed abnormally low white blood cell counts with a
relative lymphocytosis, macrocytosis with red blood cells, and haemoglobin at
borderline values. In two of the women blood values normalised within one year
after cessation of exposure. The work area was well ventilated and the authors
suggest that exposure occurred predominantly or exclusively via skin (65).
One case report describes two workers preparing screens for use in textile
printing. The mandril was cleaned by hand rubbing with acetone. During the
energy crisis in the spring of 1974, acetone was replaced by EGME. In August the
same year, one worker developed symptoms initially interpreted as encefalopathy,
bone marrow depression and pancytopenia. He was replaced by another man who
developed similar but less severe symptoms within a month. The two men re-
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covered within several weeks and one week, respectively, after exposure was
discontinued. Air measurements revealed levels of about 8 ppm EGME at the
work site. No protective equipment was used (88).
Ambient air levels of 4-20 ppm and breathing zone levels of 5.4-8.5 ppm
EGME (2-h time-weighted averages) were recorded in a cohort of 65 workers
engaged in production and packaging of EGME. Non-significant tendencies
towards reductions in white blood cell count and haemoglobin were seen in 40
exposed workers, as compared to 25 unexposed controls. A subgroup of 6
exposed and 9 unexposed individuals were examined more thoroughly. Ten-
dencies towards reductions in white blood cell count, haemoglobin, testicular size,
sperm count, serum testosterone, and serum FSH along with a tendency towards
increased serum luteinising hormone were found. No gross abnormalities or clini-
cally meaningful deviations in haematological or fertility indices were seen (17).
Out of 73 shipyard painters examined, 10% were anaemic and 5% granulo-
cytopenic, compared to 0% in unexposed controls. Exposure levels were 0-5.6
(mean 0.8 ppm, median 0.4) ppm EGME and 0-21.5 (mean 2.6, median 1.2) ppm
EGEE. Review of company records documented that most of these abnormalities
were acquired during employment. According to the authors there was no expo-
sure to lead or other chemicals known to cause haematological effects (125).
Changes in lymphocyte subpopulations, similar to those seen in immuno-
deficiency and immunogenetic forms of aplastic anaemia, were detected in nine
floorers exposed to organic solvents, as compared to unexposed controls. Solvent
exposure included EGME (mean 6.1, maximum 150 mg/m3), EGEE (mean 4.8,
maximum 53 mg/m3), ethylene glycol monobutyl ether (EGBE), butanol, iso-
butanol, toluene, xylene, methyl ethyl ketone and methyl isobutyl ketone. Judging
by solvent levels in blood, the predominant exposure was EGME (mean 0.4,
maximum 9.7 mg/L). Changes in peripheral lymphocytes included decreases in
total T cells and T helper cells, and increases in NK cells and B cells, whereas the
suppressor cell count was unaffected. In addition, there were tendencies towards
decreases in haemoglobin and red blood cell count. According to the authors, it is
not known whether the observed change in lymphocyte counts is an indicator of
early haematological and/or immunological effects which may eventually cause
disorders of the haematopoietic and/or lymphopoetic system (20).
8.3. Genotoxic effects
No studies were found dealing with genotoxic endpoints in humans exposed to
either EGME or EGMEA.
8.4. Carcinogenic effects
Acute myeloid leukaemia (198 cases) was studied in a French case-control study.
For each case and control, exposure to glycol ethers was assessed in a blinded
fashion by an expert in industrial hygiene. The exposure assessment was based on
a job description obtained by an interview and a questionnaire. No significantly
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elevated odds ratio for any group of glycol ether was seen. The odds ratio for
exposure to group I glycol ethers (including EGME, EGMEA, EGEE, EGEEA,
and a number of other ethylene glycol methyl and ethyl ethers) was 0.62 (95% CI
0.33-1.15, 26 cases). The only odds ratios above one in group I were those for
exposure level 3 (OR 1.12, 95% CI 0.42-3.03) and latency below 11 years (OR
1.26, 95% CI 0.29-5.47) (number of cases not reported). The odds ratios for acute
myeloid leukemia of the type FAB M2 (number of cases not reported) were higher
than one in all glycol ether groups except group I, although none of the increases
were statistically significant (46).
8.5. Reproductive and developmental effects
8.5.1. Effects in men
A case-control study was conducted among first time patients at a clinic for
reproductive disorders. The study group consisted of 1019 cases diagnosed as
infertile or subfertile and 475 controls diagnosed as normally fertile by spermio-
grams. Possible exposure to ethylene glycol ethers was assessed by the presence
of the urinary metabolites. In total, ethoxyacetic acid (EAA), suggesting exposure
to EGEE or its acetate ester, was detected in 39 cases and 6 controls (odds ratio of
3.11, p = 0.004). In contrast, MAA was only found in one case and two controls
(130). Thus, the study supports an effect of EGEE but is inconclusive with respect
to EGME. Whereas the expected latency period between exposure and sperm
effects is several weeks, presence of acid metabolite in urine indicates exposure
during the last few days. Therefore, exposure misclassification and, hence, under-
estimation of the true risk is highly probable.
The semen of 73 painters and 40 controls who worked in a large shipyard was
examined. Painters had an increased prevalence of oligospermia (10/73 versus
0/40 in the control group) and azoospermia (4/73 versus 0/40) and an increased
odds ratio for a lower sperm count per ejaculate (odds ratio 1.9, 95% CI 0.6-5.6),
while smoking was controlled. There was no difference in fertility between
groups. The industrial hygiene survey revealed exposures to 0-17.7 mg/m3 EGME
with a mean of 2.6 mg/m3 and 0-80.5 mg/m3 EGEE with a mean of 9.9 mg/m3
(time-weighted averages). Urinalysis of EAA suggested extensive dermal
exposure (126).
8.5.2. Effects in women
An increased frequency of spontaneous abortions was noted in women employed
in semiconductor industry. Spontaneous abortions were assessed by structured
interviews, blinded with respect to occupational history. Increased risk was
observed in the ”diffusion” (18 pregnancies, 39% abortions, relative risk 2.2, 95%
CI 1.1-3.6) and photolitographic (16 pregnancies, 31% abortions, relative risk 1.8,
95% CI 0.8-3.3) processes. The frequency of spontaneous abortions in unexposed
controls (398 pregnancies) was 18%. The diffusion process was associated with
exposure to arsine, phosphine, and diborane while the photolitographic process
involved glycol ethers, xylene, toluene, and hexamethyl disilane. According to the
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authors, general population studies have usually reported spontaneous abortion
ratios in the 10-20% range (92). Following this report several epidemiologic
studies were initiated in the semiconductor industry.
An  extensive study of reproductive outcome in the semiconductor industry was
published in 1995 (103). In industrial hygiene surveys it was found that 15-20%
of the work sites used negative photoresist chemicals containing usually 3%
EGME. All personal samples revealed air levels below 10 ppb EGME, whereas
the average exposure to other glycol ethers were 22 ppb EGEEA and 8 ppb
propylene glycol monomethyl ether acetate (PGMEA, 1-methoxypropyl acetate)
(40). Exposure to ethylene glycol ethers was highly correlated with exposure to
xylene and n-butylacetate (41).
The  risk of spontaneous abortions was studied in a historical cohort covering
904 pregnancies and 113 clinical abortions among 6088 employees in 14 semi-
conductor industries. A higher frequency of  spontaneous abortions was seen in
fabrication (15.0%) compared to non fabrication employees (10.4%) with a
relative risk of 1.43 (95% CI 0.95-2.09) after controlling for age, smoking,
ethnicity, education, income, year of pregnancy, and stress by logistic regression.
The highest risk was seen in masking (17.5% spontaneous abortions, relative risk
1.78, 95% CI 1.17-2.62). Within masking, the highest risk was found in
etching-related processes (22.2% spontaneous abortions, relative risk 2.08, 95%
CI 1.27-3.19) (8). In a follow-up study, the outcome of 891 pregnancies was
examined in relation to exposure factors. Fabrication-room workers exposed to
photoresist and developed solvents, including ethylene glycol ethers (EGME,
EGEE and their acetates), and fluoride compounds used in etching (mostly so-
called buffered-oxide etch, an aqueous solution of hydrofluoric acid and
ammonium fluoride) were at greater risk (relative risk 3.21, 95% CI 1.29-5.96),
whereas fabrication workers without these exposures showed no increase in
spontaneous abortions (116).
In a prospective study at the same companies 403 women were followed for
five menstrual cycles. Daily urine samples were analysed to confirm clinical
spontaneous abortions and early foetal losses. After control for opportunity to
become pregnant, use of oral contraceptive, and age, a significantly reduced
fecundability was seen in dopant workers (adjusted fecundability ratio 0.22, 95%
CI 0.05-0.96, for clinical pregnancies) and the same tendency in workers exposed
to ethylene glycol ethers (adjusted fecundability ratio 0.37, 95% CI 0.1-1.2) (28).
Of 19 pregnancies in the cohort, 12 (63%) ended in spontaneous abortion
compared to 33 pregnancies and 15 abortions (46%) among controls. Logistic
regression to control for smoking, ethnicity, income, education, and previous
pregnancies and abortions demonstrated that this increase was statistically
significant. Among women exposed to ethylene glycol ethers all 3 pregnancies
ended in spontaneous abortion (relative risk 2.0, 95% CI 1.5-2.8) (29). In a
parallel study, the menstrual cycle of 402 women was followed by means of
questionnaires, diaries and daily urine sampling for assay of reproductive
hormones. Thin film and ion implantation workers had significantly longer
menstrual cycles (36.1 days) than non fabrication workers (32.0 days). In addition,
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thin film, ion implantation and photolitography workers had significantly higher
variability in cycle length (34).
In an overview of the semiconductor industry study, Schenker and colleagues
concluded that the association between spontaneous abortions and fabrication
work is strengthened by the fact that similar findings were obtained in different
populations and in historical as well as prospective cohorts. The findings are also
consistent with that of other investigators. Further, the historical cohort suggested
an association with fluorides and photoresist or developer chemicals (ethylene
glycol ethers, n-butyl acetate, and xylene). Exposure to these chemicals was
highly correlated limiting the ability to analyse the outcome of exposure to any
single substance. Another important finding was the absence of an independent
association of spontaneous abortions with dopant gases (arsenic, phosphorous,
boron, antimony), cleaning solvents (acetone, isopropanol, methanol), electro-
magnetic fields, or radio frequency radiation (104).
In a study of 454 past  pregnancies among 1368 semiconductor employees,
tendencies towards increased risk of spontaneous abortions were seen in wafer
fabrication (odds ratio 1.6, 95% CI 0.8-3.4) and in nonfabrication but chemically
exposed women (odds ratio 2.0, 95% CI 0.9-4.7) after control for age, alcohol
during pregnancy and salary type. The risk of stillbirth showed a similar tendency.
According to the authors, wafer fabrication is associated with exposure to
ethylene glycol ethers as well as other organic solvents, the most common being
xylene, n-butylacetate, acetone, and 1,1,1-trichloroethane. However, no hygienic
measurements were conducted in this study (94).
Reproductive outcome was studied in a cohort of female employees (561
pregnancies) and spouses of male employees (589 pregnancies) in two semi-
conductor manufacturing plants. Increased risks of spontaneous abortion (22
pregnancies, relative risk 2.8, 95% CI 1.4-5.6) and subfertility (more than one
year of unprotected intercourse to conceive, relative risk 4.6, 95% CI 1.6-13.3)
were seen among the female employees with the highest potential for exposure to
ethylene glycol ethers. Both of these risks exhibited a significant dose-response
relation with potential ethylene glycol ether exposure. A tendency towards
subfertility was seen among spouses of male employees (relative risk 1.7, 95% CI
0.7-4.3). Glycol ethers specifically mentioned were diethylene glycol dimethyl
ether (DEGDME) and EGEEA, with levels below 0.2 ppm in the high exposure
group. No increases in risk were seen in women exposed to  n-butylacetate,
N-methyl-2-pyrrolidon, or xylene without concurrent potential exposure to glycol
ethers (18).
A common characteristic of the semiconductor industry epidemiologic studies
is that data on air levels of contaminants are scarce. The few available data indi-
cate exposure to ethylene glycol ethers in the sub-ppm range. In a separate study,
analysis of about 400 air samples revealed average levels of 0.1 ppm EGME and
0.01 ppm EGMEA (93). Another common feature is that no exposure to repro-
ductive toxicants, other than ethylene glycol ethers, could be demonstrated.
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8.5.3. Teratogenic effects
A woman was exposed to EGMEA by dermal contact and probably also by
inhalation during two pregnancies. Both children suffered from hypospadia. The
family history and medical examination showed no overt risk factor other than the
EGMEA exposure. The risk for isolated hypospadia is reportedly between 1 in
300 and 1 in 800 whereas that of repeated hypospadia (the risk when hypospadia
has already occurred in a sibling) is 1 in 24 (10).
A total of 44 patients in Matamoros, Mexico, had a peculiar phenotype with
facial and musculoskeletal malformations and mental retardation. All were born
1971-1977. Based on this finding, a case-control study was performed, consider-
ing the 44 patients as cases and healthy siblings as controls. Another control group
was formed by 90 patients in the same region with other malformations or mental
retardation. In all cases, but in none of the controls, the mother had been working
in the same factory during pregnancy. The factory manufactured radio and tele-
vision capacitors  and was operating between 1970 and 1977. Work practices
included dipping the hands in a solution mainly consisting of EGME and ethylene
glycol. No other chemical exposures were mentioned by the authors. Ventilation
was absent and gloves or breathing masks were not used. No quantitative data on
exposure are available. Work was associated with signs of acute intoxication,
fatigue, vertigo, nausea, and vomiting. Of the 44 patients, 32 were the only sibling
affected in the family. In none of these 32 cases were there any family history of
malformations or any familiar relationship between cases. A closer investigation
of 28 patients revealed that all had facial malformations and musculoskeletal
defects in the spine, hands, and feet and that about one half also expressed ocular
and otological defects (100, 101).
Congenital malformations were studied in a European collaborative case-
control study (991 cases, 1144 controls) by combining six registers in four
countries. Based on structured interviews on occupational history, potential
exposure to different types of  glycol ethers were assessed for each trimester by
occupational hygienists. According to a preliminary report, there was a significant
excess of mothers exposed to glycol ethers during the first trimester in the groups
of oral clefts (odds ratio 2.0, 95% CI 1.1-4.1), central nervous system
malformations (odds ratio 1.8, 95% CI 1.1-3.3) and musculoskeletal
malformations (odds ratio 1.6, CI 0.9-2.8) were noted (Ha et al. 1996). The results
are remarkable, considering the high level of uncertainty in exposure
categorisation which tends to decrease the odds ratios. Notably, as many as 20%
of the controls and 27% of the cases were classified as exposed to glycol ethers
during the first trimester. However, only one of the cases was considered exposed
to type 1 glycol ethers, i.e.  EGME, EGEE or their acetates.
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9. Dose-Effect and Dose-Response Relationships
Impaired cell division has been demonstrated in mouse foetal liver cells in vitro
after addition of 10 m mol/L MAA (43). According to a toxicokinetic model (128)
this concentration would correspond to 8 h exposure at 1 ppm EGME.
Dose-effect and dose-response relationships in laboratory animals are illustrated
by Tables 1 and 2.
The first effects occurring at low doses after oral administration are as follows.
In a single study in monkey, increased embryo lethality was reported after oral
exposure to 12 mg per kg and day during gestation (105) (Table 1). An immuno
stimulating effect was observed in rat at 15 mg/kg/d (21). At 25 mg/kg/d, testes
and sperm defects were seen in rabbit (9, 31) and prolonged gestational time,
reduced litter size, and increases in malformations in rat (121, 123, 124). Doses of
50 mg/kg/d resulted in thymus alterations, immunosuppression, foetal toxicity,
and malformations in rodents and completely disrupted spermatogenesis in
rabbits. Doses around 100 mg/kg/d induced similar but more severe effects and, in
addition, bone marrow depression, impaired haematopoiesis, and reduced fertility.
Neurochemical deviations were seen in the offspring of female as well as male
rats exposed to 25 ppm EGME during gestation and prior to mating, respectively
(Table 2). These deviations were seen in the absence of overt maternal or paternal
toxicity. Inhalation exposure of pregnant rodents to 50 ppm EGME resulted in
foetal toxicity, skeletal variations, and malformations in parallel with reduced
maternal weight gain. Notably, most of these effects are seen in all species and all
exposure routes examined and at approximately the same exposure levels. Based
on the inhalation data in Table 2, a no observed effect level (NOEL) of 10 ppm for
rats and mice and of 3 ppm for rabbits may be deduced (Hanley 1984), cited by
(25). The oral gavage data in Table 1 suggest a NOEL of 12 mg/kg/d for male
rabbits, whereas no NOELs can be identified for monkeys, rats, and mice.
Abnormal peripheral blood picture, disturbed haematopoiesis, reduced testes
size, and oligospermia have been observed after occupational exposure to EGME
at air levels between 0.4 and 10 ppm EGME and with additional dermal exposure
(Table 3). The observed effects are in good agreement with those seen in labora-
tory animals at somewhat higher air levels of EGME and are most likely due to
EGME, even if other exposure factors cannot be completely ruled out in each
case.
Female reproductive effects, expressed as disturbed menstrual cycle, sub-
fertility, and increased frequency of spontaneous abortions, have been demon-
strated in women working in the semiconductor industry. Also these effects are in
agreement with the findings on EGME in animal experiments. Furthermore,
ethylene glycol ethers have been attributed by the investigators as the most
plausible agent and EGME appears to be the most potent reproductive toxin
among the glycol ethers. Still, the importance of EGME in relation to other
exposure factors is unclear. The exposure levels of EGME in the semiconductor
industry were apparently in the sub-ppm range.
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10. Conclusions
Based on experiences from occupational exposure as well as animal data the
critical effect of ethylene glycol monomethyl ether (EGME) may be impairment
of reproduction or haematopoiesis.
EGME and its acetate ester (EGMEA) are efficiently absorbed by inhalation as
well as via dermal penetration. Dermal absorption may contribute substantially to
the total uptake following skin contact with liquids or vapours containing EGME
or EGMEA. EGMEA is rapidly converted to EGME in the body and the two
substances are equally toxic in animals. Therefore, EGME and EGMEA should be
considered as equally hazardous to man.
Effects on peripheral blood, haematopoiesis, testes, and sperm have been re-
ported at exposure levels of EGME ranging between 0.4 and 10 ppm, and with
additional, possibly substantial, dermal exposure. In addition, severe malforma-
tions and disturbance of blood formation have been linked with exposure to
EGME or EGMEA at unknown, probably high, levels. Embryonic deaths in
monkeys, disturbed immune system in rats, and impaired spermatogenesis in
rabbits have been reported after daily oral doses of 12, 15, and 25 mg per kg body
weight, respectively.
In several studies, increased frequency of spontaneous abortions, disturbed
menstrual cycle, and subfertility have been demonstrated in women working in
the semiconductor industry. The contribution of EGME in relation to other
exposure factors is unclear.
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11. Summary
Johanson G. Criteria Document for Swedish Occupational Standards. Ethylene
glycol monomethyl ether and ethylene glycol monomethyl ether acetate. Arbete
och Hälsa 1999:13;1-43.
Ethylene glycol monomethyl ether (EGME) and its acetate ester (EGMEA) are
highly flammable, colourless, volatile liquids with very good solubility properties.
They are used in paints, lacquers, stains, inks and surface coatings, silk-screen
printing, photographic and photo lithographic processes, e.g. in the semiconductor
industry, textile and leather finishing, production of food-contact plastics, and as
an anti-icing additive in hydraulic fluids and jet fuel.
EGME and EGMEA are efficiently absorbed by inhalation as well as via dermal
penetration. Dermal absorption may contribute substantially to the total uptake
following skin contact with liquids or vapours containing EGME or EGMEA.
EGMEA is rapidly converted to EGME in the body and the two substances are
equally toxic in animals. Therefore, the two substances should be considered as
equally hazardous to man.
Effects on peripheral blood, testes, and sperm have been reported at
occupational exposure levels ranging between 0.4 and 10 ppm EGME in air, and
with additional, possibly substantial, dermal exposure. Severe malformations and
disturbed haematopoiesis have been linked with exposure to EGME and EGMEA
at unknown, probably high, levels. Embryonic deaths in monkeys and impaired
spermatogenesis in rabbits have been reported after daily oral doses of 12 and 25
mg per kg body weight, respectively. In several studies, increased frequency of
spontaneous abortions, disturbed menstrual cycle, and subfertility have been
demonstrated in women working in the semiconductor industry. The contribution
of EGME in relation to other exposure factors in the semiconductor industry is
unclear.
Keywords: Dermal uptake, ethylene glycol monomethyl ether, ethylene glycol
monomethyl ether acetate, haematotoxicity, 2-methoxyethanol, 2-methoxyethyl
acetate, occupational exposure, reproductive toxicity, toxicity.
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12. Summary in Swedish
Johanson G. Criteria Document for Swedish Occupational Standards. Ethylene
glycol monomethyl ether and ethylene glycol monomethyl ether acetate. Arbete
och Hälsa 1999:13;1-43.
Etylenglykolmonometyleter (EGME) och dess acetatester (EGMEA) är
lättantändliga, färglösa, flyktiga vätskor med mycket goda löslighetsegenskaper.
De används i färger, lacker, bläck, silkscreenfärger, fotografiska och fotolito-
grafiska processer bland annat inom halvledarindustrin, textil- och läderbe-
arbetning, plastförpackningar avsedda för livsmedel, samt som antifrysmedel i
hydraulvätskor och flygplansbränsle.
EGME och EGMEA absorberas effektivt via lungor och hud. Hudabsorption
kan bidra till en stor del av det totala upptaget efter hudkontakt med vätske- eller
ångformig EGME eller EGMEA. EGMEA ombildas snabbt till EGME i kroppen
och de båda ämnena är lika toxiska i djurförsök. Därför bör de två ämnena
betraktas som likvärdiga med avseende på hälsorisker.
Påverkan på blodbild, testiklar och spermiebildning har setts hos yrkesmässigt
exponerade män vid nivåer av på mellan 0,4 och 10 ppm EGME i luft, och med
sannolikt betydande hudexponering. Allvarliga missbildningar och störd blod-
bildning och har kopplats till yrkesmässig exponering för EGME och EGMEA i
okända, troligen höga nivåer. Fosterdöd hos apor och nedsatt spermiebildning hos
kanin har setts efter dagliga orala doser på 12 respektive 25 mg per kg kroppsvikt.
I flera studier har ökad frekvens spontanaborter, störd menstruation och nedsatt
fertilitet påvisats för kvinnor i halvledarindustrin. Betydelsen av EGME i
förhållande till andra agens i halvledarindustrin är oklar.
Nyckelord: etylenglykolmetyleter, etylenglykolmetyleteracetat, hematologiska
effekter, hudupptag, 2-metoxietanol, 2-metoxietylacetat, reproduktionstörande
effekter, toxiska effekter, yrkesmässig exponering
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